Do phenothiazines contribute to tumour regressions in lymphokineactivated killer cell/interleukin-2 treatments of renal cell cancer?
Sir -Phenothiazines are known to exhibit antitumour activity (Belkin & Hardy, 1957) . They are used routinely for the prevention of treatment-induced nausea in cancer patients not only during treatment with cytotoxic drugs but also during administration of lymphokine -activated killer (LAK) cells and interleukin-2 (IL-2). With the LAK cell/IL-2 treatment tumour regressions are mainly observed in renal cell cancer patients and melanoma patients (Rosenberg et al., 1985) . The present experiments were performed to examine a possible cytostatic activity of phenothiazines on human renal cancer cells. Four commercially available phenothiazines were tested (Table I) on human renal cancer cells as recently described (Sauter & Cogoli, 1987) .
Growth inhibition was observed with all of the four phenothiazines examined at concentrations similar to that of nitrogen mustard (Table I ). The maximal effect was reached between 20 and 40h of drug:cell contact. Drug-cell contact as short as seven minutes already produced a definite growth inhibition (Figure 1 ).
The phenothiazine concentrations necessary to cause growth inhibition of renal cancer cells in vitro are around 20pM whereas plasma levels of chlorpromazine rarely exceed 0.6/M (Simpson et al., 1980) . Despite this 30-fold difference in concentrations an in vivo antitumour activity of phenothiazines is quite possible due to selective high concentrations in certain tumour tissues (Fairchild et al., 1982) : Interestingly enough LAK cell/IL-2 treatments induce tumour regressions in melanomas (Rosenberg et al., 1985) where chlorpromazine is known to accumulate (Fairchild et al., 1982) . If 
